SLDB (Solid Biosciences) Short Interest

View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Solid Biosciences's Short Interest

For the Biotechnology subindustry, Solid Biosciences's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's Short Interest distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's Short Interest falls into.

Save Embed

;

Save Embed

;

Solid Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129

Website

https://www.solidbio.com

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Executives

Clare Kahn	director	141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Gabriel Brooks	officer: Chief Medical Officer	C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
David T Howton	officer: See Remarks	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Paul Herzich	officer: Chief Technology Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan	officer: Chief Regulatory Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Kevin Tan	officer: CFO & Treasurer	20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot	director, officer: Chief Executive Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Alexander Cumbo	director, officer: President and CEO	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jennifer Marlowe	officer: CSO, FA & Cardiac	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris	officer: Chief Scientific Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Perceptive Venture Advisors, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003